ストックスクリーナーアプリを入手
0.775
3.09%
0.0232
アフターアワーズ：
.76
-0.015
-1.94%
前日終値:
$0.7518
開ける：
$0.7413
24時間の取引高:
213.02K
Relative Volume:
0.54
時価総額：
$32.52M
収益：
$2.93M
当期純損益:
$-25.30M
株価収益率:
-1.4451
EPS:
-0.5363
ネットキャッシュフロー:
$-33.59M
1週間 パフォーマンス:
+9.15%
1か月 パフォーマンス:
+6.93%
6か月 パフォーマンス:
-10.81%
1年 パフォーマンス:
-17.80%
1日の値動き範囲:
$0.7306
$0.7799
1週間の範囲:
$0.6961
$0.7799
52週間の値動き範囲:
$0.565
$1.31
Scynexis Inc Stock (SCYX) Company Profile
Compare SCYX vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.775 | 31.55M | 2.93M | -25.30M | -33.59M | -0.5363 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-01-22 | 開始されました | Guggenheim | Buy |
| 2021-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-11 | アップグレード | Needham | Hold → Buy |
| 2018-06-27 | 開始されました | Maxim Group | Buy |
| 2017-10-24 | 開始されました | Guggenheim | Buy |
| 2017-07-10 | 開始されました | ROTH Capital | Buy |
| 2017-05-09 | ダウングレード | Needham | Buy → Hold |
| 2017-03-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-20 | 開始されました | H.C. Wainwright | Buy |
| 2016-10-07 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | 再開されました | Brean Capital | Buy |
| 2016-08-17 | 開始されました | Guggenheim | Buy |
| 2016-08-09 | 繰り返されました | Needham | Buy |
| 2016-08-09 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | 開始されました | Brean Capital | Buy |
| 2015-12-29 | 開始されました | WBB Securities | Speculative Buy |
| 2015-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-06-10 | 開始されました | Needham | Buy |
| 2014-05-29 | 開始されました | Canaccord Genuity | Buy |
| 2014-05-29 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Scynexis Inc (SCYX) 最新ニュース
SCYX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above 50 Day Moving Average – What’s Next? - Defense World
SCYNEXIS, Inc. (SCYX) Competitors - Meyka
Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC - GuruFocus
SCYNEXIS (SCYX) Initiates Phase 1 Trial for New Antifungal Thera - GuruFocus
SCYNEXIS doses first patients in SCY-247 IV formulation trial - Investing.com
SCYNEXIS, Inc. Initiates Phase 1 Trial for Intravenous Antifungal SCY-247 Following FDA Designations - Quiver Quantitative
SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 - The Manila Times
SCYNEXIS starts dosing trial for antifungal targeting resistant infections - Stock Titan
Can SCYNEXIS Inc. disrupt its industryJuly 2025 Trade Ideas & AI Driven Price Predictions - mfd.ru
Does SCYNEXIS Inc. align with a passive investing strategyTrade Entry Report & Expert-Curated Trade Recommendations - mfd.ru
Short Squeeze: Will SCYNEXIS Inc benefit from rate cutsJuly 2025 PostEarnings & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Kingdon Capital exits Scynexis (SCYX) stake in amended 13G/A filing - Stock Titan
Can SCYNEXIS Inc. expand into new marketsWeekly Risk Report & Consistent Growth Equity Picks - mfd.ru
Market Moves: Is SCYNEXIS Inc backed by strong institutional buyingQuarterly Portfolio Report & AI Forecast Swing Trade Picks - baoquankhu1.vn
Invasive Fungal Infections Market to Witness Upsurge in Growth at a CAGR of 11.4% (in the US) During the Forecast Period (2025-2034) | DelveInsight - The Malaysian Reserve
FOMO Trade: Does SCYNEXIS Inc have pricing powerJuly 2025 Levels & Community Driven Trade Alerts - baoquankhu1.vn
Swing Trade: Is SCYNEXIS Inc backed by strong institutional buyingMarket Performance Summary & Weekly Consistent Profit Watchlists - baoquankhu1.vn
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting - marketscreener.com
Scynexis (SCYX) to Present Data on Advanced Antifungal Drug at K - GuruFocus
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) - The Manila Times
New antifungal SCY-247 shows potent activity against deadly drug-resistant fungi - stocktitan.net
Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky - Sahm
Aug Macro: Can SCYNEXIS Inc expand into new marketsQuarterly Earnings Summary & Safe Entry Trade Reports - baoquankhu1.vn
JERSEY CITYFDA grants fast track and QIDP designations to SCYNEXIS drug - Investing.com Nigeria
Scynexis (SCYX) Gains FDA Designations for Antifungal Therapy SC - GuruFocus
Scynexis receives FDA qualified infectious disease product and fast track designations for SCY-247 - marketscreener.com
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 - The Manila Times
FDA fast-tracks new antifungal aimed at deadly Candida auris infections - Stock Titan
Breakout Move: Is SCYNEXIS Inc benefiting from innovation trendsMarket Sentiment Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Aug Volume: Is SCYNEXIS Inc stock trending bullishWeekly Trade Analysis & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
FEDERATED HERMES, INC. Acquires Additional Shares in SCYNEXIS Inc. - GuruFocus
Retail Trends: Can SCYNEXIS Inc expand into new marketsWeekly Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
RSI Check: Is SCYNEXIS Inc benefiting from innovation trendsWeekly Trend Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Jobs Data: Will SCYNEXIS Inc stock continue dividend increasesJuly 2025 Levels & Community Driven Trade Alerts - Bộ Nội Vụ
Published on: 2026-01-11 17:42:44 - Улправда
SCYNEXIS halts phase 3 MARIO trial, raising new questions for ibrexafungerp’s growth path - MSN
Why SCYNEXIS Inc. (135A) stock is listed among top recommendationsJobs Report & Low Risk Investment Opportunities - ulpravda.ru
Why hedge funds are buying SCYNEXIS Inc. stockWeekly Trade Summary & AI Driven Price Predictions - Улправда
Gains Report: Does SCYNEXIS Inc stock trade at a discount to peersWeekly Trade Recap & Expert Curated Trade Ideas - Bộ Nội Vụ
How SCYNEXIS Inc. stock compares to industry benchmarksOptions Play & Daily Stock Momentum Reports - Улправда
Why SCYNEXIS Inc. stock is trending among retail tradersResistance Breakout Alerts & Free Rapid Return Acceleration - bollywoodhelpline.com
Portfolio Update: How SCYNEXIS Inc stock compares to industry benchmarksJuly 2025 Highlights & Free Safe Capital Growth Stock Tips - moha.gov.vn
SCYNEXIS granted Nasdaq extension to regain bid price compliance - MSN
What analysts say about SCYNEXIS Inc 135A stockFundamental Strength Indicators & Build Wealth With Expert Timing Advice - earlytimes.in
Scynexis receives 180-day extension from Nasdaq to meet listing requirements - Investing.com
Scynexis granted 180-day extension by Nasdaq to regain compliance with minimum bid price requirement - marketscreener.com
SCYNEXIS, Inc. Receives 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement - Quiver Quantitative
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - The Manila Times
Earnings Report: Why SCYNEXIS Inc. stock is trending among retail tradersAnalyst Downgrade & Long Hold Capital Preservation Plans - Улправда
SCYNEXIS Earnings Notes - Trefis
Scynexis Inc (SCYX) 財務データ
収益
当期純利益
現金流量
EPS
0.21%
1.77%
大文字化:
|
ボリューム (24 時間):